The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis

This publication has 21 references indexed in Scilit:

• The direct thrombin inhibitor hirudin
  Thrombosis and Haemostasis, 2008
• Strategies for the Management of Suspected Heparin-Induced Thrombocytopenia
  PharmacoEconomics, 2007
• Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia
  Blood, 2006
• Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patient
  Journal of Hospital Medicine, 2006
• Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings
  Journal of Thrombosis and Haemostasis, 2006
• Incidence and clinical significance of anti‐PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin‐induced thrombocytopenia
  European Journal of Haematology, 2006
• The Cost-Effectiveness of Argatroban Treatment in Heparin-Induced Thrombocytopenia
  Cardiology in Review, 2006
• Lepirudin in patients with heparin-induced thrombocytopenia – results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3
  Journal of Thrombosis and Haemostasis, 2005
• Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis
  Blood, 2005
• Pharmacoeconomics of low-molecular-weight heparins: limitations of studies comparing them to unfractionated heparin
  Expert Opinion on Pharmacotherapy, 2004